Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Update

Key Points

• Short interest surged 31.6% to 427,713 shares as of March 13, representing about 0.8% of the stock and a short-interest ratio of 1.9 days based on average daily volume.
• Analyst sentiment is broadly positive with an average rating of "Moderate Buy" and an average price target of $44.25, following upgrades and new coverage from firms including Guggenheim, Leerink and Evercore.
• Several hedge funds established new positions in the fourth quarter, institutional ownership stands at 14.20%, and the stock recently traded around $25.50 with a market cap of $1.54 billion.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 13th, there was short interest totaling 427,713 shares, a growth of 31.6% from the February 26th total of 325,076 shares. Approximately 0.8% of the company's stock are sold short. Based on an average daily volume of 220,622 shares, the short-interest ratio is currently 1.9 days.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Wall Street Zen raised Damora Therapeutics, Inc. Common Stock from a "sell" rating to a "hold" rating in a research report on Saturday, December 6th. Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research note on Monday, February 2nd. Leerink Partners initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They set an "outperform" rating and a $46.00 price objective for the company. Guggenheim reiterated a "buy" rating and issued a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Finally, Evercore initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday. They set an "outperform" rating and a $46.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $44.25.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently modified their holdings of DMRA. Ikarian Capital LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $6,574,000. Jain Global LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $2,774,000. Remedium Capital Partners LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $2,772,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $2,204,000. Finally, Connective Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $100,000. Institutional investors own 14.20% of the company's stock.

Damora Therapeutics, Inc. Common Stock Stock Down 0.5%

NASDAQ DMRA traded down $0.13 during midday trading on Friday, hitting $25.50. The company had a trading volume of 171,777 shares, compared to its average volume of 292,469. The firm has a fifty day simple moving average of $27.02 and a two-hundred day simple moving average of $19.77. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -2.11 and a beta of 1.42. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.01 and a fifty-two week high of $38.33.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.